Ilant Health raises $15M to use AI for obesity care as employers rethink costly GLP-1 coverage

The obesity drug boom promised a breakthrough in healthcare. It delivered one. It brought a new problem, too.

Employers across the United States are facing soaring costs tied to popular GLP-1 weight-loss drugs. Some companies have begun scaling back coverage, tightening eligibility requirements, or dropping benefits altogether as pharmacy spending climbs.

That tension has created an opening for startups that claim they can improve outcomes without sending healthcare costs through the roof.

Ilant Health is betting that artificial intelligence can help solve that challenge.

The New York-based HealthTech startup announced Tuesday that it has raised $15 million in Series A funding, bringing its total funding to more than $22 million. The round was led by Cornucopian Capital, with participation from naturalX, Peakbridge, Semcap AI, Evidenced, Operator Partners, and existing investors Celtic, LifeX, and AlphaLab.

Founded by former McKinsey consultant and Molina Healthcare executive Elina Onitskansky, Ilant works directly with employers and health plans that are struggling to balance rising obesity-related healthcare costs with growing demand for treatment.

The timing of the funding announcement comes as many employers reassess their approach to GLP-1 coverage. Recent reports show a growing number of organizations are reconsidering broad access to weight-loss medications as costs continue to climb. At the same time, demand for drugs such as Zepbound and Wegovy remains strong, creating pressure on employers, insurers, and healthcare providers looking for a sustainable path forward.

As employers pull back on GLP-1 coverage, Ilant Health raises $15M for AI-powered obesity care

Ilant’s pitch is straightforward: obesity should not be treated solely as a medication-access problem.

Instead, the company argues that effective obesity care requires a combination of behavioral therapy, medication, surgery when appropriate, and continuous monitoring of patient outcomes. AI plays a central role in determining which interventions are most appropriate for each individual and adjusting treatment plans over time based on clinical, behavioral, and personal data.

The company’s platform supports clinician decision-making by helping identify which patients are most likely to benefit from specific interventions, whether that involves GLP-1 drugs, non-GLP-1 medications, behavioral programs, or surgical options.

That approach reflects a broader shift taking place across healthcare.

For years, much of healthcare AI focused on administrative tasks such as documentation, scheduling, coding, and claims processing. A growing number of startups are now moving deeper into clinical decision support, using AI to help providers make treatment recommendations, identify risk factors, and personalize care plans.

Obesity care has become a particularly attractive market for those efforts.

More than 40% of U.S. adults are estimated to have obesity, according to federal health data. The introduction of highly effective GLP-1 medications has fueled unprecedented demand for treatment, creating one of the fastest-growing segments in healthcare. The surge in adoption has generated billions of dollars in revenue for drug manufacturers and left employers searching for ways to manage costs without sacrificing patient outcomes.

Ilant says its model is already producing encouraging results.

According to data released by the company, members enrolled in its programs achieve an average weight loss of 15%, alongside improvements in broader health indicators and self-reported wellbeing. The company claims its approach helps employers manage treatment spending and overall healthcare costs simultaneously.

The startup has already established relationships with major healthcare and pharmaceutical partners. Last year, Ilant announced direct contracting and pricing arrangements through Lilly’s Employer Connect program. The company is working with both Eli Lilly and Novo Nordisk, the two pharmaceutical giants at the center of the GLP-1 market.

For investors, the opportunity extends beyond weight-loss drugs.

“We believe the next generation of category-defining companies will be those that deliver outcomes as a service, not just tools or access,” said Aryeh Ganz, Founder and Managing Partner of Cornucopian Capital. “Ilant is applying that model to one of the most important and costly areas in healthcare.”

Onitskansky sees the current moment as a turning point for obesity treatment.

“Employers and health plans are facing a real dilemma right now — they are faced with either expanding access and watching pharmaceutical costs rise dramatically, or restricting access and risking rising chronic disease and cost,” she said. “That’s not a sustainable model. If we don’t change how care is delivered, we’re just paying more for the same broken system, and we risk a crisis where both chronic disease and costs are spiraling out of control.”

The debate around obesity treatment is unlikely to fade anytime soon. Demand for GLP-1 drugs continues to grow, employers remain under pressure to control healthcare spending, and AI is beginning to move beyond back-office functions into treatment decisions themselves.

Ilant is betting that the future of obesity care will belong to platforms that can deliver better outcomes while lowering costs.